Dr. Ravi B. Diwakar

1. Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers.

Authors: Korlimarla A, Ps H, Prabhu J, Ragulan C, Patil Y, Vp S, Desai K, Mathews A, Appachu S, Diwakar RB, Bs S, Melcher A, Cheang M, Sadanandam A

Journal: Transl Oncol

Published: 2022 Nov

Additional Details: 25:101511. doi: 10.1016/j.tranon.2022.101511. Epub 2022 Aug 11. Erratum in: Transl Oncol. 2023 Jan;27:101574. PMID: 35964339; PMCID: PMC9386467

2. Corrigendum to "Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers": Translational Oncology 2022 Nov; 25:101511.

Authors: Korlimarla A, Hari PS, Prabhu J, Ragulan C, Patil Y, Snijesh VP, Desai K, Mathews A, Appachu S, Diwakar RB, Srinath BS, Melcher A, Cheang M, Sadanandam A

Journal: Transl Oncol

Published: 2023 Jan

Additional Details: 27:101574. doi: 10.1016/j.tranon.2022.101574. Epub 2022 Nov 3. Erratum for: Transl Oncol. 2022 Nov;25:101511. PMID: 36517200; PMCID: PMC9782722

3. MicroRNA-mediated resistance mechanisms in NAT-treated HER2-positive breast cancer (BC): A single centre retrospective analysis from matched primary and residual tumours

Authors: Mathranda SA, Kumar P, Kumar R, Srihari S, Diwaker R, Munirathnam V, Simha V, Anantharamu S, RN S, PS H, Veeraiyan D

4. Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center

Authors: Appachu S, Diwaker RB, Vivek S, Simha VV

Journal: Indian Journal of Medical and Paediatric Oncology

Published: 2025 Apr

Additional Details: 46(02):168-73